LEADERSHIP IN THE NEUROMODULATOR MARKET. Approved by the FDA in 1989, BOTOX (botulinum toxin type a) was first used as a therapeutic  agent in ophthalmology to treat strabismus and blepharospasm. Both of these rare eye disorders can render patients visually impaired. Since then, BOTOX has evolved to become the standard of care in many parts of the world for other neuromuscular disorders, such as cervical dystonia. In some countries BOTOX is rapidly becoming a prime therapy for focal  spasticity or indications in which patients suffer localized, constricted muscles. In many countries around the world, children with juvenile cerebral palsy are administered BOTOX therapy to relax afflicted muscles and increase flexibility and mobility. This enhanced movement enables youngsters to stretch rigid muscles, learn to walk and maximize the benefits of their  physical therapy. Outside the United States, BOTOX therapy in adults has effectively decreased post-stroke spasticity and improved functional ability  in patients’ daily lives. The expanding clinical and investigational uses of the BOTOX product are credited to the same properties that made it beneficial for the very first patients: localized treatment to temporarily relax muscles or calm down an overactive gland for therapeutic benefit. No other neuromodulator on the  market can match its clinical profile, long-term use and published efficacy data.